|
|
|
|
||
Re: EPS revisions and Q1List Price of PC drugs is really meaningless as much of it is contract based and there is a rebellion against high priced generics equivalents (understand all the arguments, but this is how the industry is looking at it). Big K gains and incremental sales of orphan should be enough to beat conservative estimates. Like you I want to hear some research updates. |
return to message board, top of board |